作　　者： ; ;

机构地区： 江门市新会人民医院

出　　处： 《现代肿瘤医学》 2018年第24期4008-4010,共3页

摘　　要： 目的:观察R-GEMOX方案(利妥昔单抗联合吉西他滨、奥沙利铂)挽救性治疗复发、难治B细胞性非霍奇金淋巴瘤(non-Hodgkin's lymphoma,NHL)的近期疗效和毒副反应。方法:回顾性分析20例经正规标准方案治疗复发或难治的B细胞性NHL患者,采用R-GEMOX方案(利妥昔单抗375 mg/m^2,第0天;吉西他滨1 000 mg/m^2,静脉滴注,第1、8天;奥沙利铂130 mg/m^2,静脉滴注,第1天),21～28 d为一个周期,每化疗4个周期后评价疗效,每1个周期化疗后评价毒副反应。结果:20例患者中,完全缓解(complete remission,CR) 7例,部分缓解(partial remission,PR) 8例,总有效率(CR+PR)为75%。7例具有B类症状的患者,5例症状消失,1例明显改善。毒副反应可耐受。结论:R-GEMOX方案对复发难治B细胞性NHL近期疗效较好,毒副反应小,是一个值得进一步验证的补救性化疗方案。 Objective： To investigate the efficacy and toxicities of R-GEMOX regimen（ rituximab,gemcitabine,oxaliplat） in the treatment of relapsed/refractor B-cell non-Hodgkin＇s lymphoma（ NHL）. Methods： Twenty patients with relapsed or refractor B-cell NHL after medication of traditional chemotherapy accepted R-GEMOX regimen,the efficacy toxicities was evaluated after at least 4 cycles of chemotherapy,the toxicities was evaluated after at least 1 cycles of chemotherapy. Results： Of the 20 cases,7 patients were in complete remission and 8 in partial remission,resulting in an overall remission rate of 75%（ 15/20）. 5 patients symptom disappeared,and 1 in 7 cases was alleviated of type B symptoms. The toxicity was mild. Conclusion： R-GEMOX regimen was effect for recurrent or refractory B-cell NHL,and the toxicities can be tolerated. This protocol was worthy to warranted as salvage for relapsed or refractory B-cell NHL.

关 键 词： 非霍奇金淋巴瘤 利妥昔单抗 吉西他滨 奥沙利铂

领　　域： []